Workflow
Soleno Therapeutics, Inc. (SLNO) Targets EMA Approval as U.S. Launch of VYKAT XR Expands

In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Soleno Therapeutics, Inc. is one of them. Soleno Therapeutics, Inc. (NASDAQ:SLNO) tops our list for being one of the most oversold stocks. It is a clinical-stage biotech focused on rare diseases and has seen significant stock volatility in 2025 following the commercial launch of its lead product, VYKAT XR, the first FDA-approved treatment for hyperphagia in Prader-Willi Syndrome (PWS). The therapy addresses ...